Pulmonology & Critical Care
META ANALYSIS
● Meta-analysis
Hyper-oncotic Albumin Reduces Mortality in ARDS Compared to Crystalloid
Annals of medicine
Published March 28, 2026
Zhang Yan-Jie, Luo Zhu, Wang Zhen, Shao Ji-Yue, Xu Jingyuan
PubMed ↗
DOI ↗
A systematic review and meta-analysis evaluated the impact of albumin administration on mortality in adult patients with acute respiratory distress syndrome (ARDS), comparing it to crystalloid solutions. The analysis included five studies: three randomized controlled trials (RCTs) and two non-randomized studies (NRSs). The primary endpoint was 28-day mortality, with secondary outcomes including oxygenation changes and lengths of ICU and hospital stay. Overall, mortality was lower in the albumin group (33.2%, 97/292) compared to the crystalloid group (44.9%, 133/296), with an odds ratio (OR) of 0.61 (95% CI 0.43-0.85, p=0.004). While RCTs (n=204) showed no mortality benefit (OR=0.83, p=0.54), NRSs (n=384) demonstrated reduced mortality with albumin (OR=0.52, p=0.002). Specifically, hyper-oncotic albumin was associated with lower mortality in NRSs (OR=0.40, p=0.02) but not in RCTs (OR=0.74, p=0.57). Iso-oncotic albumin showed no mortality benefit (OR=0.88, p=0.72). Significant improvements in oxygenation were noted on the first (p=0.05) and second days (p<0.0001) post-administration. The trial sequential analysis highlighted the need for more high-quality RCTs to confirm these findings and clarify the clinical role of hyper-oncotic albumin in ARDS management.
AI Accuracy Review: 8/10
· Auto-published
When patients suffer from acute respiratory distress syndrome (ARDS), every decision counts. A recent analysis suggests that using hyper-oncotic albumin, a type of protein solution, may reduce mortality compared to traditional crystalloid fluids. In the studies reviewed, 33.2% of patients receiving albumin died, compared to 44.9% of those receiving crystalloid solutions. This is significant because it highlights a potential way to improve survival rates in critically ill patients. However, the results varied between different types of studies. While non-randomized studies showed a strong benefit from hyper-oncotic albumin, randomized controlled trials did not find the same advantage. Additionally, patients receiving albumin experienced better oxygenation, especially in the first two days of treatment. Despite these promising findings, the analysis emphasizes the urgent need for larger, high-quality studies to confirm the benefits of hyper-oncotic albumin and clarify its role in treating ARDS. For patients and families facing this serious condition, these insights could lead to better treatment options in the future.
What this means for you: Hyper-oncotic albumin may lower mortality in ARDS patients compared to standard fluids.
View Original Abstract ↓
BACKGROUND: To evaluate the association between albumin administration as volume replacement and mortality in adult ARDS patients, we performed this meta-analysis and trial sequential analysis (TSA).
METHODS: We searched databases including PubMed, Science Direct, Scopus, Web of Science databases and Cochrane Central Register of Controlled Trials up to 12 December 2024. We screened trials that included adult ARDS patients and compared albumin with crystalloid. The 28-day mortality served as the primary endpoint, while the oxygenation change, the length of ICU stay and the length of hospital stay were designated as secondary outcomes. To clarify the differing concentrations of albumin, we formed two distinct subgroups: the hyper-oncotic albumin subgroup (≥20%) and the iso-oncotic albumin subgroup (4%∼5%). Statistical synthesis was performed with Cochrane Review Manager 5.4.1, employing random-effects models. To mitigate random errors, TSA was implemented with α = 0.05 and β = 0.20 parameters.
RESULTS: The analysis incorporated 5 publications: 3 randomized controlled trials (RCTs) and 2 non-randomized studies (NRSs). Overall mortality was lower in the albumin group (33.2%, 97/292) than in the crystalloid group (44.9%, 133/296) (OR = 0.61, 95%CI 0.43-0.85, = 0.004). RCTs ( = 204) showed no benefit (OR = 0.83, = 0.54), but NRSs ( = 384) demonstrated reduced mortality (OR = 0.52, = 0.002). Hyper-oncotic albumin was associated with lower mortality in NRSs (OR = 0.40, = 0.02) but not in RCTs (OR = 0.74, = 0.57). Iso-oncotic albumin showed no benefit (OR = 0.88, = 0.72). Regarding the impact of albumin on oxygenation, significant improvements in oxygenation were observed only on the first ( = 0.05) and second days ( < 0.0001). The TSA indicated a continued need for high-quality RCTs.
CONCLUSIONS: Our analysis suggests that hyper-oncotic albumin may reduce mortality and improve early oxygenation in ARDS patients compared to crystalloids. Larger RCTs are urgently needed to validate these findings and define their potential role in clinical management.
